The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the USAID MVDP, the partners will conduct studies to determine the effectiveness of Crucell"s novel prime-boost vaccine approach against the malaria parasite, Plasmodium falciparum. This approach uses Crucell"s proprietary recombinant adenoviruses (a type of virus associated with the common cold and other mild respiratory infections) to deliver a malaria antigen to the immune system.